RNA replicon derived from a coronavirus with complete or partial deletion of: the gene encoding the E protein and at least 4 genes encoding genus accessory proteins selected from: 3, 4a, 4b and 5, in the case of MERS-CoV. Method of preparation thereof, and their use in vaccine compositions.

The present invention relates to a composition comprising (a) a recombinant rhabdovirus vector capable of forming a virus particle and expressing an immunogen of a betacoronavirus, wherein the immunogen comprises at the C-terminus a heterologous transmembrane anchor for the incorporation of the immunogen into (i) the cell membrane of infected cells, and (ii) the envelope of the virus particle, and/or (b) a glycoprotein (G) protein gene deleted and in trans G protein complemented recombinant rhabdovirus vector capable of forming a virus-like particle (VLP) and expressing an immunogen of a betacoronavirus, wherein the immunogen comprises at the C-terminus a heterologous transmembrane anchor for the incorporation of the immunogen into (i) the cell membrane of infected cells, and (ii) the VLP.

Provided herein are recombinant polypeptides comprising a SARS-CoV-2 S1 protein binding domain polypeptide and a GM-CSF polypeptide, polynucleotide sequences encoding the same, virus-like particles comprising the same, and methods for using these compositions for the treatment of a SARS-CoV-2 infection in a subject, and for detection of a SARS-CoV-2 antibodies in a subject.

This invention relates to SARS-CoV-2 viruses adapted with nanoluciferase reporter molecules and mouse-adapted SARS-CoV-2 viruses, compositions including the same and methods of use thereof.

Virus-like particles (VLPs) of mammalian-hosted viruses, such as SARS-CoV and influenza viruses, have been recombinantly produced from Vero cells. The VLPs closely emulate the exterior of authentic virus particles and are highly immunogenic. They can elicit not only humoral but also cellular immune responses in a mammal. Compositions and methods related to the VLPs are also described.

This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.

An immunogenic composition effective for eliciting an immune response against cells that present coronavirus S protein and/or coronavirus M protein derived antigens on a virus-like-particle (VLP) system. In a method embodiment, the antigen presenting VLP is administered to a mammal, such as a human, to elicit an immune response against coronavirus S protein and/or coronavirus M protein. A preferred method embodiment may include at least one additional dose of immunogenic composition to enhance the immune response effectiveness of the coronavirus vaccine.

Microneedle and microneedle devices including implantable tips (e.g., silk-based tips) for sustained dermal delivery of a coronavirus and/or influenza vaccine, kits, as well as methods of manufacturing and using the same are described herein. In other embodiments, compositions and methods for controlled- or sustained-administration of a coronavirus vaccine and/or an influenza vaccine to provide improved immunogenicity and/or broad-spectrum immunity to a subject are also described.

Virus-like particles, compositions and antibody detection tests with virus-like particles, and a method of producing virus-like particles are disclosed. The method includes generating a modified viral genome based on a viral genome, wherein a portion of the viral genome is removed to generate the modified viral genome configured to yield virus-like particles that are unable to replicate, and producing one or more virus-like particles using the modified viral genome.

This invention relates to SARS-CoV-2 viruses adapted with nanoluciferase reporter molecules and mouse-adapted SARS-CoV-2 viruses, compositions including the same and methods of use thereof.